Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection
MT Newswires Live
Sep 22
(Updates with the latest stock price movement in the headline and the first paragraph.)
Amneal Pharmaceuticals (AMRX) shares rose more than 10% in Monday trading after the company said Friday the US Food and Drug Administration approved its lanreotide injection, 120 mg/0.5 mL.
The company said it will immediately launch the product, which references SOMATULINE Depot and received Competitive Generic Therapy designation from the FDA.
Lanreotide injection is indicated for the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors and carcinoid syndrome, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.